<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Clemente-Moragon A</submitter><funding>European Research Council</funding><pagination>1001-1011</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8404624</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>78(10)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Severe coronavirus disease-2019 (COVID-19) can progress to an acute respiratory distress syndrome (ARDS), which involves alveolar infiltration by activated neutrophils. The beta-blocker metoprolol has been shown to ameliorate exacerbated inflammation in the myocardial infarction setting.&lt;h4>Objectives&lt;/h4>The purpose of this study was to evaluate the effects of metoprolol on alveolar inflammation and on respiratory function in patients with COVID-19-associated ARDS.&lt;h4>Methods&lt;/h4>A total of 20 COVID-19 patients with ARDS on invasive mechanical ventilation were randomized to metoprolol (15 mg daily for 3 days) or control (no treatment). All patients underwent bronchoalveolar lavage (BAL) before and after metoprolol/control. The safety of metoprolol administration was eva</pubmed_abstract><journal>Journal of the American College of Cardiology</journal><pubmed_title>Metoprolol in Critically Ill Patients With COVID-19.</pubmed_title><pmcid>PMC8404624</pmcid><funding_grant_id>819775</funding_grant_id><pubmed_authors>Galan-Arriola C</pubmed_authors><pubmed_authors>Ibanez B</pubmed_authors><pubmed_authors>Ioan AM</pubmed_authors><pubmed_authors>Lopez-Alvarez M</pubmed_authors><pubmed_authors>Oliver E</pubmed_authors><pubmed_authors>Fernandez I</pubmed_authors><pubmed_authors>Rodriguez-Gonzalez L</pubmed_authors><pubmed_authors>Serrano Del Castillo C</pubmed_authors><pubmed_authors>Fuster V</pubmed_authors><pubmed_authors>Clemente-Moragon A</pubmed_authors><pubmed_authors>Santos A</pubmed_authors><pubmed_authors>Martinez-Milla J</pubmed_authors><pubmed_authors>Gomez-Talavera S</pubmed_authors><pubmed_authors>Perez-Calvo C</pubmed_authors><pubmed_authors>Flandes J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Metoprolol in Critically Ill Patients With COVID-19.</name><description>&lt;h4>Background&lt;/h4>Severe coronavirus disease-2019 (COVID-19) can progress to an acute respiratory distress syndrome (ARDS), which involves alveolar infiltration by activated neutrophils. The beta-blocker metoprolol has been shown to ameliorate exacerbated inflammation in the myocardial infarction setting.&lt;h4>Objectives&lt;/h4>The purpose of this study was to evaluate the effects of metoprolol on alveolar inflammation and on respiratory function in patients with COVID-19-associated ARDS.&lt;h4>Methods&lt;/h4>A total of 20 COVID-19 patients with ARDS on invasive mechanical ventilation were randomized to metoprolol (15 mg daily for 3 days) or control (no treatment). All patients underwent bronchoalveolar lavage (BAL) before and after metoprolol/control. The safety of metoprolol administration was eva</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Sep</publication><modification>2026-05-10T05:45:46.578Z</modification><creation>2022-02-11T10:14:51.939Z</creation></dates><accession>S-EPMC8404624</accession><cross_references><pubmed>34474731</pubmed><doi>10.1016/j.jacc.2021.07.003</doi></cross_references></HashMap>